Zidovudine Articles
GW not to obtain exclusive license for Verex' Aztec
15 January 1996
FDA Year-End Approvals Round-Up
8 January 1996
BioChem Pharma and GW get new Epivir approval
18 December 1995
Bayer Highlights New Immuno Technology
4 December 1995
Glaxo Wellcome Set To Launch 3TC In Its First Market
27 November 1995
Glaxo Wellcome Unveils Revamped Pipeline
20 November 1995
...And Roche Gets Recommendation For Invirase
13 November 1995
3TC Gains FDA Panel Recommendation For Approval
13 November 1995
Triangle, Led By Ex-Wellcome R&D Chief, Financing Deal
13 November 1995
Fast Growth Forecast For Antivirals
30 October 1995
Aronex : AR177 trials
16 October 1995
New Phase II Data On Merck & Co's Crixivan
9 October 1995
Two-Year Data For BioChem Pharma's 3TC
9 October 1995
Delta Trial Gives Boost To AIDS Community
2 October 1995
B-MS Shows Benefits Of Antiretroviral Therapy
25 September 1995
Glaxo Wellcome Reveals Integration Effects
11 September 1995
Roche Files NDA In USA For Invirase
11 September 1995
Glaxo Wellcome: Building For The Long Term
21 August 1995
GATT Changes Effect 42% Of US Drug Patents
21 August 1995
More Turns In Retrovir Patent Dispute
21 August 1995
Bristol-Myers research operations
31 July 1995
B-MS Files For New Zerit Indication
31 July 1995
Robotic Handling Systems Transform Drug Discovery
31 July 1995
Glaxo Wellcome Files First Dossier For 3TC
10 July 1995
Merck pipline report
3 July 1995
Roche's Invirase Made Available In USA
3 July 1995
Paracelsian HIV Drug Ups Zidovudine Effects
19 June 1995
Glaxo Wellcome Patent Battles Continue
19 June 1995
Biochem Pharma To File NDA For 3TC In June
15 May 1995
Roche's Saquinavir Safe In HIV-Infected Patients
24 April 1995
Columbia's AIDS Drug Enters Ph II/III In UK
20 March 1995
Expanded Access Urged For Protease Inhibitors
13 March 1995
US Industry Welcomes China Trade Treaty
6 March 1995
Merger Forms Cancer And Anti-Infectives Specialist
6 March 1995
Genta Jago Files IND
27 February 1995
Controversy Over New French Drug Policy
27 February 1995
Zidovudine Arm Of ACTG 152 Halted
20 February 1995
Robb Claims Wellcome Is Undervalued By Glaxo
20 February 1995
Lamivudine/Zidovudine Combination Promising
13 February 1995
Abbott's Protease Inhibitor
13 February 1995
Glaxo, Wellcome Product Lines Are Complementary
6 February 1995
Lamivudine In AIDS: Ph II/III Results
6 February 1995
Do Wellcome Results Justify Higher Bid
6 February 1995
Glaxo Bids L8.9 Billion To Take Over Wellcome
30 January 1995
FDA C'tee Gives Thumbs Down For OTC Zovirax
23 January 1995
Burroughs Wellcome Outlook Reviewed
19 December 1994
Vertex Begins VX-710 Clinical Trials
12 December 1994
Novopharm To Fight On Over AZT
12 December 1994
Wellcome Patents Upheld In USA
28 November 1994
European Stock Comment
28 November 1994
Lamivudine Enhances Zidovudine Efficacy
28 November 1994
Retrovir Final Results On Mother Baby Transmission
7 November 1994
Magaziner, Mrs Clinton Moved Aside
7 November 1994
HIV Therapy Options Examined
31 October 1994
Canada: Province's "Secret Pact With Drug Firms"
24 October 1994
New Wellcome AntiHIV Shows Promise
10 October 1994
MicroProbe To FileIND For MPC-531 Antiviral In 1995
26 September 1994
Hivid Approved In UK
19 September 1994
Phase II Data On Saquinavir
12 September 1994
Retrovir Approval For Pregnant Women
22 August 1994
New AIDS Therapy
22 August 1994
France To Ease Key Drug Prescribing
22 August 1994
HIVID Approved For Monotherapy In USA
15 August 1994
Zidovudine Trial Adds Nothing New
15 August 1994
Wellcome Details HIV Research Plans
15 August 1994
Panel Backs Indication Extension For Retrovir
8 August 1994
Vertex Predicts Four Drugs In Trials By End-1994
25 July 1994
European Stock Comment
25 July 1994
Four-Month Results At Wellcome As Expected
25 July 1994
Retrovir/Zovirax May Prolong HIV Survival
25 July 1994
French Antiviral PB-100 Ruled As Ineffective
25 July 1994
Americans "May Be Paying Twice For Their drugs"
25 July 1994
APO-ZIDOVUDINE APPROVED IN GREECE
11 July 1994
PROMPT APPROVAL OF B-MS' STAVUDINE
4 July 1994
DDA DERIVATIVE FOR HIV
27 June 1994
UK LAUNCH OF DIDANOSINE
27 June 1994
"MURDER DOCTORS," SAY AIDS EXTREMISTS
20 June 1994
ROCHE ACCELERATES SAQUINAVIR FILING
13 June 1994
US FDA COMMITTEE COMMENTS ON STAVUDINE
30 May 1994
WELLCOME DENIES RETROVIR PRICE CUTS
2 May 1994
FIRMS TO SHARE AIDS DRUG TRIAL DATA
25 April 1994
EUROPEAN STOCK COMMENT
18 April 1994
FINAL CONCORDE RESULTS CONFIRM EXPECTATIONS
18 April 1994
JAPANESE COs TOO DEPENDENT ON HOME MKT
11 April 1994
WELLCOME'S PRICE WAR IN PORTUGAL
4 April 1994
WELLCOME'S SHARE PRICE WOES
4 April 1994
INTERIM PRETAX UP 12% AT WELLCOME
28 March 1994
WELLCOME TO DEVELOP 3TC?
28 March 1994
TRIALS BEGIN ON PMEA AIDS TREATMENT
28 March 1994
HIVID AS EFFECTIVE AS VIDEX
21 March 1994
US AIDS MARKET "TO DOUBLE BY 1999"
21 March 1994
ZALCITABINE AS EFFECTIVE AS DIDANOSINE
14 March 1994
EARLY-USE RETROVIR ENDORSED
14 March 1994
TRIPLE THERAPY FOR AIDS
7 March 1994
WELLCOME FACES PATENT CHALLENGE
7 March 1994
MERCK'S AIDS DRUG RESEARCH STUMBLES
7 March 1994
COST-CUTTING IN SPANISH HEALTH CARE
7 March 1994
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
